Epidemiology of genital warts in the British population: implications for HPV vaccination programmes.


Journal

Sexually transmitted infections
ISSN: 1472-3263
Titre abrégé: Sex Transm Infect
Pays: England
ID NLM: 9805554

Informations de publication

Date de publication:
08 2019
Historique:
received: 30 07 2018
revised: 06 11 2018
accepted: 25 11 2018
pubmed: 7 2 2019
medline: 22 1 2020
entrez: 7 2 2019
Statut: ppublish

Résumé

To estimate the prevalence of, and describe risk factors for, genital warts (GWs) in the British population, following the introduction of the bivalent (human papillomavirus (HPV)-16/18) vaccination programme in girls, and prior to the switch to quadrivalent (HPV-6/11/16/18) vaccine (offering direct protection against GWs) and compare this with GW diagnoses in the prevaccination era. Natsal-3, a probability sample survey in Britain, conducted in 2010-2012, interviewed 9902 men and women aged 16-44. Natsal-2, conducted in 1999-2001, surveyed 11 161 men and women aged 16-44. Both surveys collected data on sexual behaviour and sexually transmitted infection diagnoses using computer-assisted interview methods. In Natsal-3, 3.8% and 4.6% of sexually experienced men and women reported ever having a diagnosis of GWs, with 1.3% of men and 1.7% of woman reporting a GWs diagnosis in the past 5 years. GWs were strongly associated with increasing partner numbers and condomless sex. Diagnoses were more frequent in men who have sex with men (MSM) (11.6% ever, 3.3% past 5 years) and in women reporting sex with women (10.8% ever, 3.6% past 5 years). In the age group who were eligible for vaccination at the time of Natsal-3 (16-20 years), a similar proportion of same-aged women reported a history of GWs in Natsal-2 (1.9%, 1.1-3.4) and Natsal-3 (2.6%, 1.5-4.4). These data provide essential parameters for mathematical models that inform cost-effectiveness analyses of HPV vaccination programmes. There was no evidence of population protection against GWs conferred by the bivalent vaccine. Even with vaccination of adolescent boys, vaccination should be offered to MSM attending sexual health clinics.

Identifiants

pubmed: 30723185
pii: sextrans-2018-053786
doi: 10.1136/sextrans-2018-053786
pmc: PMC6678036
doi:

Substances chimiques

Papillomavirus Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

386-390

Subventions

Organisme : Medical Research Council
ID : G0701757
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 084840
Pays : United Kingdom

Informations de copyright

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: AMJ has been a Governor of the Wellcome Trust since 2011. The other authors declare that they have no conflicts of interest.

Références

Lancet Oncol. 2012 May;13(5):487-500
pubmed: 22445259
Vaccine. 2015 Nov 17;33(46):6264-7
pubmed: 26431981
Sex Transm Infect. 2017 Mar;93(2):125-128
pubmed: 27365492
Lancet. 2013 Nov 30;382(9907):1795-806
pubmed: 24286785
Lancet Infect Dis. 2017 Dec;17(12):1293-1302
pubmed: 28965955
Clin Infect Dis. 2017 Mar 1;64(5):580-588
pubmed: 28011615
Am J Public Health. 2007 Jun;97(6):1126-33
pubmed: 17463372
J Infect. 2017 Apr;74(4):393-400
pubmed: 28126492
Future Microbiol. 2015;10(1):35-51
pubmed: 25598336
Sex Transm Infect. 2012 Apr;88(3):212-7
pubmed: 22261135
Cancer Epidemiol Biomarkers Prev. 2015 May;24(5):842-53
pubmed: 25737331
Virol J. 2013 May 01;10:137
pubmed: 23634957
J Infect Dis. 2013 Nov 1;208(9):1391-6
pubmed: 24092907
Br J Cancer. 2015 Apr 28;112(9):1585-93
pubmed: 25791874
Clin Infect Dis. 2016 Aug 15;63(4):519-27
pubmed: 27230391
Papillomavirus Res. 2017 Jun;3:36-41
pubmed: 28626810
Sex Transm Infect. 2014 Mar;90(2):84-9
pubmed: 24277881
BMC Infect Dis. 2013 Jan 25;13:39
pubmed: 23347441
Sex Transm Infect. 2009 Dec;85(7):499-502
pubmed: 19837728
Vaccine. 2017 Jun 5;35(25):3342-3346
pubmed: 28499554
J Infect Dis. 2013 Nov 1;208(9):1397-403
pubmed: 24092908
Sex Transm Infect. 2011 Oct;87(6):464-8
pubmed: 21813567
J Infect Dis. 2018 Aug 14;218(6):911-921
pubmed: 29917082
Lancet. 2001 Dec 1;358(9296):1835-42
pubmed: 11741621
Sex Transm Infect. 2011 Oct;87(6):458-63
pubmed: 21636616
Sex Transm Infect. 2015 May;91(3):214-9
pubmed: 25305210

Auteurs

Pam Sonnenberg (P)

Mortimer Market Centre, Institute for Global Health, University College London, London, UK p.sonnenberg@ucl.ac.uk.

Clare Tanton (C)

Mortimer Market Centre, Institute for Global Health, University College London, London, UK.
Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine (LSHTM), London, UK.

David Mesher (D)

Centre for Infectious Disease Surveillance and Control (CIDSC), Public Health England, London, UK.

Eleanor King (E)

Mortimer Market Centre, Institute for Global Health, University College London, London, UK.

Simon Beddows (S)

Virus Reference Department, Public Health England, London, UK.

Nigel Field (N)

Mortimer Market Centre, Institute for Global Health, University College London, London, UK.

Catherine H Mercer (CH)

Mortimer Market Centre, Institute for Global Health, University College London, London, UK.

Kate Soldan (K)

Centre for Infectious Disease Surveillance and Control (CIDSC), Public Health England, London, UK.

Anne M Johnson (AM)

Mortimer Market Centre, Institute for Global Health, University College London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH